These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Open innovation: share or die.. Talaga P Drug Discov Today; 2009 Nov; 14(21-22):1003-5. PubMed ID: 19778629 [No Abstract] [Full Text] [Related]
3. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development. Perakslis ED; Van Dam J; Szalma S Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001 [No Abstract] [Full Text] [Related]
4. Overcoming the obstacles in the pharma/biotech industry: 2008 update. Graul AI; Revel L; Rosa E; Cruces E Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298 [TBL] [Abstract][Full Text] [Related]
5. Deal watch: is deal-making becoming more difficult? Borshell N Nat Rev Drug Discov; 2011 Jun; 10(6):404. PubMed ID: 21629282 [No Abstract] [Full Text] [Related]
6. Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry. Cottens S; Eaton M; Fuhr J; Geary S; Johnson DS; Li G; Raveglia L; Robertson GM; Westwell A Future Med Chem; 2011 Nov; 3(15):1863-72. PubMed ID: 22023030 [TBL] [Abstract][Full Text] [Related]
7. The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Vallance P; Williams P; Dollery C Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455 [No Abstract] [Full Text] [Related]
8. The evolving role of collaboration in biotechnology. Gower JM Nat Biotechnol; 1998 May; 16 Suppl():31-2. PubMed ID: 9591261 [No Abstract] [Full Text] [Related]
9. Discontinued drugs in 2010: oncology drugs. Williams R Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127 [TBL] [Abstract][Full Text] [Related]
10. Grants4Targets: an open innovation initiative to foster drug discovery collaborations. Dorsch H; Jurock AE; Schoepe S; Lessl M; Asadullah K Nat Rev Drug Discov; 2015 Jan; 14(1):74-6. PubMed ID: 25430867 [No Abstract] [Full Text] [Related]
11. Today's biotech industry in India. Suresh N Biotechnol J; 2009 Mar; 4(3):291-4. PubMed ID: 19296434 [No Abstract] [Full Text] [Related]
12. Translational regenerative medicine research: essential to discovery and outcome. Mason C; Dunnill P Regen Med; 2007 May; 2(3):227-9. PubMed ID: 17511558 [No Abstract] [Full Text] [Related]
13. Pharmaceutical pipeline. Lowen T Minn Med; 2011 Oct; 94(10):16-8. PubMed ID: 23256279 [No Abstract] [Full Text] [Related]
14. The COPD Pipeline XIII. Gross NJ COPD; 2011 Dec; 8(6):464-5. PubMed ID: 22149408 [No Abstract] [Full Text] [Related]
15. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science. Woosley RL; Myers RT; Goodsaid F Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457 [TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical sciences in 2020. Crommelin D; Stolk P; Besançon L; Shah V; Midha K; Leufkens H Nat Rev Drug Discov; 2010 Feb; 9(2):99-100. PubMed ID: 20118959 [No Abstract] [Full Text] [Related]
18. Menelas Pangalos. Interview by Asher Mullard. Mullard A Nat Rev Drug Discov; 2013 Jun; 12(6):418. PubMed ID: 23722338 [No Abstract] [Full Text] [Related]
19. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. Lee JA; Uhlik MT; Moxham CM; Tomandl D; Sall DJ J Med Chem; 2012 May; 55(10):4527-38. PubMed ID: 22409666 [No Abstract] [Full Text] [Related]
20. Algeta and Ablynx collaborate to discover and develop targeted cancer therapies. King G Future Med Chem; 2013 Feb; 5(2):123. PubMed ID: 23476969 [No Abstract] [Full Text] [Related] [Next] [New Search]